Andrew A. Y. Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrew A. Y. Chen has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Luke Y. C. Chen
Division of Hematology University of British Columbia Vancouver British Columbia Canada
2 shared publications - Richard Schwarzkopf
Coastal Program for Rare Inflammatory Diseases, Nova Scotia Health and Department of Psychology and Neuroscience, Dalhousie University Halifax Nova Scotia Canada
2 shared publications - Anupama Ghimire
Department of Biochemistry & Molecular Biology, Dalhousie University, Halifax NS B3H 4R2, Canada
1 shared publication - Jan K. Rainey
Department of Biochemistry & Molecular Biology Dalhousie University Halifax Nova Scotia B3H 4R2 Canada
1 shared publication - Janet Roberts
J. Roberts, MD, MPH, Division of Rheumatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia
1 shared publication - John Paul Frampton
School of Biomedical Engineering, Dalhousie University
1 shared publication
Latest Publications
- 22 April 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (8) , 1808-1810
HAVCR2 in subcutaneous panniculitis‐like T cell lymphoma: comment on the article by Chambers et al
- 22 April 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (8) , 1808-1810
HAVCR2 in subcutaneous panniculitis‐like T cell lymphoma: comment on the article by Chambers et al
- Open Access
- 31 March 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 215, 102-117
A bioengineered recombinant spider silk provides targeted G-protein-coupled receptor activation
- 31 March 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 215, 102-117
Open AccessA bioengineered recombinant spider silk provides targeted G-protein-coupled receptor activation
- Open Access
- 8 September 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (4)
Treatment of severe refractory immune neutropenia with ruxolitinib: Two cases
Two adult patients with severe immune neutropenia refractory to standard therapies achieved durable remission following treatment with the JAK inhibitor ruxolitinib. This report highlights the potential of JAK–STAT pathway inhibition for managing G-CSF and steroid-refractory immune-mediated neutropenia.
- 8 September 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (4)
Open AccessTreatment of severe refractory immune neutropenia with ruxolitinib: Two cases
Two adult patients with severe immune neutropenia refractory to standard therapies achieved durable remission following treatment with the JAK inhibitor ruxolitinib. This report highlights the potential of JAK–STAT pathway inhibition for managing G-CSF and steroid-refractory immune-mediated neutropenia.